Quest Diagnostics (DGX) Competitors $176.57 -2.76 (-1.54%) Closing price 07/2/2025 03:59 PM EasternExtended Trading$176.50 -0.07 (-0.04%) As of 05:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DGX vs. HSIC, MEDP, AMN, LH, DVA, CHE, CRVL, AMED, MD, and CCRNShould you be buying Quest Diagnostics stock or one of its competitors? The main competitors of Quest Diagnostics include Henry Schein (HSIC), Medpace (MEDP), AMN Healthcare Services (AMN), Labcorp (LH), DaVita (DVA), Chemed (CHE), CorVel (CRVL), Amedisys (AMED), Pediatrix Medical Group (MD), and Cross Country Healthcare (CCRN). Quest Diagnostics vs. Its Competitors Henry Schein Medpace AMN Healthcare Services Labcorp DaVita Chemed CorVel Amedisys Pediatrix Medical Group Cross Country Healthcare Henry Schein (NASDAQ:HSIC) and Quest Diagnostics (NYSE:DGX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment. Which has more volatility & risk, HSIC or DGX? Henry Schein has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Quest Diagnostics has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Do analysts prefer HSIC or DGX? Henry Schein currently has a consensus price target of $79.30, suggesting a potential upside of 6.47%. Quest Diagnostics has a consensus price target of $185.73, suggesting a potential upside of 5.19%. Given Henry Schein's higher possible upside, equities analysts plainly believe Henry Schein is more favorable than Quest Diagnostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Henry Schein 0 Sell rating(s) 5 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.64Quest Diagnostics 0 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.69 Do insiders and institutionals have more ownership in HSIC or DGX? 96.6% of Henry Schein shares are owned by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are owned by institutional investors. 1.1% of Henry Schein shares are owned by insiders. Comparatively, 8.2% of Quest Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer HSIC or DGX? In the previous week, Quest Diagnostics had 2 more articles in the media than Henry Schein. MarketBeat recorded 13 mentions for Quest Diagnostics and 11 mentions for Henry Schein. Quest Diagnostics' average media sentiment score of 1.12 beat Henry Schein's score of 1.11 indicating that Quest Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Henry Schein 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quest Diagnostics 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, HSIC or DGX? Quest Diagnostics has lower revenue, but higher earnings than Henry Schein. Quest Diagnostics is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHenry Schein$12.67B0.72$390M$3.2023.28Quest Diagnostics$9.87B2.00$871M$7.9122.32 Is HSIC or DGX more profitable? Quest Diagnostics has a net margin of 8.81% compared to Henry Schein's net margin of 3.21%. Quest Diagnostics' return on equity of 15.11% beat Henry Schein's return on equity.Company Net Margins Return on Equity Return on Assets Henry Schein3.21% 14.87% 5.82% Quest Diagnostics 8.81%15.11%6.65% SummaryQuest Diagnostics beats Henry Schein on 12 of the 17 factors compared between the two stocks. Get Quest Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DGX vs. The Competition Export to ExcelMetricQuest DiagnosticsMED IndustryMedical SectorNYSE ExchangeMarket Cap$20.02B$3.96B$5.54B$20.53BDividend Yield1.78%1.27%5.39%3.77%P/E Ratio22.3235.0326.1727.85Price / Sales2.00100.15413.5537.49Price / Cash13.2824.6336.1321.91Price / Book2.884.388.024.55Net Income$871M$189.47M$3.15B$984.95M7 Day Performance-0.30%-3.50%1.48%2.31%1 Month Performance1.69%-4.47%3.66%4.85%1 Year Performance25.32%7.78%34.68%13.81% Quest Diagnostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DGXQuest Diagnostics4.9367 of 5 stars$176.57-1.5%$185.73+5.2%+29.2%$20.02B$9.87B22.3256,000Positive NewsHSICHenry Schein3.0144 of 5 stars$73.05-0.3%$79.30+8.6%+13.5%$8.89B$12.67B22.8325,000Positive NewsMEDPMedpace4.4659 of 5 stars$313.86+1.0%$344.82+9.9%-19.4%$9.02B$2.16B23.965,900AMNAMN Healthcare Services4.2146 of 5 stars$20.73-0.7%$32.08+54.8%-55.8%$793.54M$2.98B-4.792,968News CoverageLHLabcorp4.3664 of 5 stars$262.39+0.7%$276.08+5.2%+28.3%$21.96B$13.01B30.3375,500Positive NewsInsider TradeDVADaVita4.2823 of 5 stars$142.40+0.5%$164.50+15.5%+3.1%$10.75B$12.82B14.1176,000Positive NewsCHEChemed4.9676 of 5 stars$485.18-13.3%$645.00+32.9%-13.0%$7.10B$2.43B23.6315,695Analyst ForecastHigh Trading VolumeCRVLCorVel1.2345 of 5 stars$102.78-0.8%N/A+17.6%$5.29B$895.59M55.965,075AMEDAmedisys2.887 of 5 stars$98.39+0.5%$100.75+2.4%-0.8%$3.23B$2.35B36.3119,000News CoverageMDPediatrix Medical Group1.4487 of 5 stars$14.33+2.1%$16.67+16.3%+95.7%$1.23B$2.01B-14.194,305CCRNCross Country Healthcare3.8439 of 5 stars$13.05+2.0%$17.93+37.4%-4.1%$427.78M$1.34B-24.628,205 Related Companies and Tools Related Companies Henry Schein Alternatives Medpace Alternatives AMN Healthcare Services Alternatives Labcorp Alternatives DaVita Alternatives Chemed Alternatives CorVel Alternatives Amedisys Alternatives Pediatrix Medical Group Alternatives Cross Country Healthcare Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:DGX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quest Diagnostics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Quest Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
